MGC Pharmaceuticals sees strong market outlook as global phytocannabinoid market gains traction

MGC Pharma has commenced clinical trials for three of its key Phytomedicine products CannEpil®, CogniCann® and CimetrA™.

Phase IIb clinical trial is being conducted at the Schindler Hospital in Israel on the safety and efficacy of CannEpil® as an add-on treatment in children and adolescents with refractory epilepsy.

The expected time to marketing authorisation is four years.

Phase II Clinical Trial is being carried out with the University of Notre Dame in Perth to evaluate the potential behavioural benefits CogniCann® may have on patients with dementia and Alzheimer’s disease.

The expected time to marketing authorisation is five years.

CimetrA™, does not contain cannabinoids and is designed from four natural ingredients as a phytomedicine to target viral infections with inflammatory complications.

In March 2021, CimetrA™ received the Ethics Committee approvals from the Rambam Health Care Campus and the Nazareth Hospital EMMS in Israel for Phase III clinical trials on patients diagnosed with coronavirus.

The trial will evaluate the efficacy and safety of CimetrA™ in the treatment of moderate hospitalised patients diagnosed with coronavirus (COVID-19) on a large patient group.

The trial is expected to begin in early April and conclude in September, with interim and full results expected in June and October respectively.

The Phase III trial is currently undergoing regulatory approvals for additional clinical sites in Israel and Brazil.

The expected time to fast-tracked marketing authorisation is less than one year.

Read the article by Rachel Middleton in ProActive.